众生药业：公司RAY0221是超长效的GLP-1/GIP/GCG三受体激动剂，具有良好的药代特性

Core Viewpoint - The company highlights the advantages of its weight loss drug, RAY0221, which is a long-acting GLP-1/GIP/GCG triple receptor agonist with promising pharmacokinetic properties, potentially allowing for administration every two weeks or more [1] Group 1 - The drug RAY0221 is characterized as a long-acting triple receptor agonist targeting GLP-1, GIP, and GCG [1] - The pharmacokinetic profile of RAY0221 is noted to be favorable, indicating its potential for less frequent dosing [1] - The company aims to leverage these properties to enhance clinical outcomes in weight management [1]